Staphylococcal toxic shock syndrome 2000-2006: Epidemiology, clinical features, and molecular characteristics

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  DeVries, Aaron S ^a   Lesher, Lindsey ^a   Schlievert, Patrick M ^b   Rogers, Tyson ^c,d   Villaume, Lourdes G ^a,c,e   Danila, Richard ^a   Lynfield, Ruth ^a  

^a MINNESOTA DEPARTMENT OF HEALTH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d MEDTRONIC INC   (United States)

^e Sharp Rees Stealy Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMMUNOGLOBULIN; OXACILLIN; QUINOLONE DERIVATIVE; SUPERANTIGEN; TETRACYCLINE; TOXIC SHOCK SYNDROME TOXIN 1; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; ERYTHRODERMA; FEMALE; FEVER; HUMAN; HYPOTENSION; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENSTRUATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PULSED FIELD GEL ELECTROPHORESIS; RASH; REVIEW; RISK FACTOR; SCHOOL CHILD; SEA GENE; SEB GENE; SEC GENE; SKIN EXFOLIATION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TOXIC SHOCK SYNDROME; ARTICLE; INFANT; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PATHOPHYSIOLOGY; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; UNITED STATES;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MINNESOTA; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 80051511204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022997     Document Type: Review

References (42)

1. Stevens FA, (1927) The occurence of Staphylococcus aureus infection with a scarlitiniform rash. JAMA 88: 1957-1958.
2. Todd J, Fishaut M, Kapral F, Welch T, (1978) Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 2: 1116-1118.
3. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, et al. (1980) Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 303: 1436-1442.
4. Davis JP, Chesney PJ, Wand PJ, LaVenture M, (1980) Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 303: 1429-1435.
5. Schlievert PM, Osterholm MT, Kelly JA, Nishimura RD, (1982) Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome. Ann Intern Med 96: 937-940.
6. Bonventre PF, Linnemann C, Weckbach LS, Staneck JL, Buncher CR, et al. (1984) Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis 150: 662-666.
7. Osterholm MT, Forfang JC, (1982) Toxic-shock syndrome in Minnesota: results of an active-passive surveillance system. J Infect Dis 145: 458-464.
8. Gaventa S, Reingold AL, Hightower AW, Broome CV, Schwartz B, et al. (1989) Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis 11 (Suppl 1): S28-34.
9. Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, et al. (1999) Toxic shock syndrome in the United States: surveillance update, 1979 1996. Emerg Infect Dis 5: 807-810.
10. Kain KC, Schulzer M, Chow AW, (1993) Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 16: 100-106.
11. Rosene KA, Copass MK, Kastner LS, Nolan CM, Eschenbach DA, (1982) Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med 96: 865-870.
12. Ferry T, Bes M, Dauwalder O, Meugnier H, Lina G, et al. (2006) Toxin gene content of the Lyon methicillin-resistant Staphylococcus aureus clone compared with that of other pandemic clones. J Clin Microbiol 44: 2642-2644.
13. Durand G, Bes M, Meugnier H, Enright MC, Forey F, et al. (2006) Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France. J Clin Microbiol 44: 847-853.
14. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F, (2006) Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 193: 1495-1503.
15. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, et al. (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355: 666-674.
16. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, et al. (2005) Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352: 1436-1444.
17. Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY, et al. (1982) Nonmenstrual toxic shock syndrome: A review of 130 cases. Ann Intern Med 96: 871-874.
18. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, et al. (2003) Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290: 2976-2984.
19. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, et al. (2006) Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 42: 647-656.
20. Edgeworth JD, Yadegarfar G, Pathak S, Batra R, Cockfield JD, et al. (2007) An outbreak in an intensive care unit of a strain of methicillin-resistant Staphylococcus aureus sequence type 239 associated with an increased rate of vascular access device-related bacteremia. Clin Infect Dis 44: 493-501.
21. Stolz SJ, Davis JP, Vergeront JM, Crass BA, Chesney PJ, et al. (1985) Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J Infect Dis 151: 883-889.
22. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, et al. (2002) Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359: 1819-1827.
23. Matsuda Y, Kato H, Yamada R, Okano H, Ohta H, et al. (2003) Early and definitive diagnosis of toxic shock syndrome by detection of marked expansion of T-cell-receptor VBeta2-positive T cells. Emerg Infect Dis 9: 387-389.
24. Chini V, Dimitracopoulos G, Spiliopoulou I, (2006) Occurrence of the enterotoxin gene cluster and the toxic shock syndrome toxin 1 gene among clinical isolates of methicillin-resistant Staphylococcus aureus is related to clonal type and agr group. J Clin Microbiol 44: 1881-1883.
25. Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, et al. (2003) Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47: 196-203.
26. Okii K, Hiyama E, Takesue Y, Kodaira M, Sueda T, et al. (2006) Molecular epidemiology of enteritis-causing methicillin-resistant Staphylococcus aureus. J Hosp Infect 62: 37-43.
27. Schlievert PM, Tripp TJ, Peterson ML, (2004) pp. 2875-2876 Reemergence of Staphylococcal Toxic Shock Syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 Surveillance Period.
28. Centers for Disease Control and Prevention (1997) Toxic Shock Syndrome; 1997 Case Definition. http://www.cdc.gov/ncphi/disss/nndss/casedef/toxicss1997.htm. Accessed: 2008 Nov 11.
29. Hajjeh RA, Relman D, Cieslak PR, Sofair AN, Passaro D, et al. (2002) Surveillance for Unexplained Deaths and Critical Illnesses Due to Possibly Infectious Causes, United States, 1995-1998. Emerging Infectious Diseases 8: 145.
30. Lesher L, Devries A, Danila R, Lynfield R, (2009) Evaluation of surveillance methods for staphylococcal toxic shock syndrome. Emerg Infect Dis 15: 770-773.
31. Centers for Disease Control and Prevention (2010) Active Bacterial Core Surveillance http://www.cdc.gov/abcs/index.html. Accessed: 2011 Jan 13.
32. Schlievert PM, Case LC, (2007) Molecular analysis of staphylococcal superantigens. Methods Mol Biol 391: 113-126.
33. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, et al. (2003) Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: Establishing a national database. J Clin Microbiol 41: 5113-5120.
34. Petitti DB, Reingold AL, (1989) Update through 1985 on the incidence of toxic shock syndrome among members of a prepaid health plan. Rev Infect Dis 11 (Suppl 1): S22-26; discussion S26-27.
35. Lange J, Steinbuch M, (2005) Trends in the Incidence of Toxic Shock Syndrome. 43rd IDSA Conference 101.
36. Jamart S, Denis O, Deplano A, Tragas G, Vandergheynst A, et al. (2005) Methicillin-resistant Staphylococcus aureus toxic shock syndrome. Emerg Infect Dis 11: 636-637.
37. Como-Sabetti K, Harriman KH, Buck JM, Glennen A, Boxrud DJ, et al. (2009) Community-associated methicillin-resistant Staphylococcus aureus: trends in case and isolate characteristics from six years of prospective surveillance. Public Health Rep 124: 427-435.
38. Centers for Disease Control and Prevention, Active Bacterial Core Surveillance (2009) ABCs Report: Neisseria meningitidis, 2009 http://www.cdc.gov/abcs/reports-findings/survreports/mening09.html. Accessed: 2011 Feb 10.
39. Centers for Disease Control and Prevention, Active Bacterial Core Surveillance (2009) ABCs Report: Group A Streptococcus, 2009 http://www.cdc.gov/abcs/reports-findings/survreports/gas09.html. Accessed: 2011 Feb 10.
40. Centers for Disease Control and Prevention (2011) Toxic Shock Syndrome; 2011 Case Definition http://www.cdc.gov/ncphi/disss/nndss/casedef/toxicsscurrent.htm. Accessed: 2011 Feb 10.
41. Nelson AL, (2006) Extended-regimen contraception: Effects on menstrual symptoms and quality of life. J Fam Pract 55: S1-8.
42. Ferrero S, Abbamonte LH, Giordano M, Alessandri F, Anserini P, et al. (2006) What is the desired menstrual frequency of women without menstruation-related symptoms? Contraception 73: 537-541.